Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126396962 | 12639696 | 2 | F | 2016 | 20160808 | 20160810 | 20160816 | EXP | RU-ASTRAZENECA-2016SE85274 | ASTRAZENECA | 72.00 | YR | F | Y | 0.00000 | 20160817 | MD | RU | RU |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126396962 | 12639696 | 1 | PS | IRESSA | GEFITINIB | 1 | Oral | 164550 | MG | N | U | 206995 | 150 | MG | TABLET | QD | |||
126396962 | 12639696 | 2 | SS | IRESSA | GEFITINIB | 1 | Oral | 164550 | MG | N | U | 206995 | 250 | MG | TABLET | QD | |||
126396962 | 12639696 | 3 | C | BIPHOSPHONATE | 2 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126396962 | 12639696 | 1 | Lung adenocarcinoma |
126396962 | 12639696 | 2 | Lung adenocarcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126396962 | 12639696 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126396962 | 12639696 | Malignant neoplasm progression | |
126396962 | 12639696 | Metastases to bone | |
126396962 | 12639696 | Metastases to lung |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126396962 | 12639696 | 1 | 20150319 | 201607 | 0 | |
126396962 | 12639696 | 2 | 20150318 | 201607 | 0 |